OCEANIC-AF study stopped early due to lack of efficacy
Bayer | Science For Better Life | Corporate News
by
4M ago
Berlin, November 19, 2023 – OCEANIC-AF, a phase III study investigating asundexian compared to apixaban (a direct oral anticoagulant) in patients with atrial fibrillation at risk for stroke is being stopped early. This decision is based on the recommendation of the study’s Independent Data Monitoring Committee (IDMC) as part of ongoing surveillance which showed an inferior efficacy of asundexian versus the control arm. Bayer will further analyze the data to understand the outcome and publish the data. Available safety data are consistent with previously reported safety profiles of asundexian ..read more
Visit website
Third quarter below prior year as expected – Group outlook confirmed
Bayer | Science For Better Life | Corporate News
by
4M ago
Leverkusen, November 8, 2023 – Bayer has confirmed its Group outlook for 2023 after posting third-quarter figures that were down against the previous year. “The results came in largely as we expected, knowing that Q3 is never our strongest quarter. The important message is that, based on where we are and what we see for the remaining quarter, we are confirming the updated 2023 guidance,” CEO Bill Anderson said on Wednesday when presenting the company’s Quarterly Statement. “We know that this requires a strong fourth quarter. We’re fully focused on delivering exactly that – and the team is conf ..read more
Visit website
Bayer introduces agricultural system for direct-seeded rice with potential to reduce greenhouse gas emissions and water use by up to 40 percent
Bayer | Science For Better Life | Corporate News
by
5M ago
Manila, Philippines, October 16, 2023 – On UN World Food Day, Bayer announced the introduction of its direct-seeded rice (DSR) system at the 6th International Rice Congress in Manila. Moving from transplanted puddled rice cultivation to direct-seeded rice can help farmers to reduce water use by up to 40 percent, greenhouse gas emissions (GHG) by up to 45 percent and reduce farmers’ dependence on scarce and costly manual labor by up to 50 percent. The introduction of the DSR system is fully in line with Bayer’s recently announced approach to regenerative agriculture which will enable farmers to ..read more
Visit website
Bayer to partner with Twist Bioscience to accelerate drug discovery
Bayer | Science For Better Life | Corporate News
by
6M ago
Berlin, October 5, 2023 – Bayer AG has entered into an antibody discovery, option, and license agreement with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon platform. The company’s “Library of Libraries”, a collection of synthetic antibody libraries that harness innovative structural and developability features to cover a wide range of antibody drug targets, is tailored to address specific challenges in antibody discovery. It has the potential to increase the probability of success of antibody discovery programs across indications and focus areas ..read more
Visit website
More than 70% of farmers have already seen large impacts of climate change on their farm, new global research across 8 countries reveals
Bayer | Science For Better Life | Corporate News
by
6M ago
Monheim, September 21, 2023 – 71% of farmers say that climate change already has a large impact on their farm, and even more are worried about the impact this will have in the future. 73% have experienced increasing pest and disease pressure. On average farmers estimate that their incomes had reduced by 15.7% due to climate change in the past two years. One in six farmers even identifies income losses of over 25% during this period. These are some of the key findings from the “Farmer Voice” survey, published today, which reveals the challenges facing farmers around the world as they try to mit ..read more
Visit website
Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator
Bayer | Science For Better Life | Corporate News
by
6M ago
Berlin, Germany, San Diego, CA, USA, September 18, 2023 – Vividion Therapeutics, Inc. (Vividion), announced today that it has initiated dosing of patients in a Phase I oncology clinical trial of its investigational oral Kelch-like ECH Associated Protein 1 (KEAP1) activator, VVD-130037. Vividion is a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Bayer AG. The start of the trial represents ..read more
Visit website
Gene Editing: Pairwise and Bayer start new five-year multi-million Dollar collaboration to further advance short-stature corn
Bayer | Science For Better Life | Corporate News
by
7M ago
Durham, N.C., Monheim, Germany, August 29, 2023 – Pairwise, a food and agriculture company known for bringing the first gene-edited food to the U.S. market, and Bayer today announced a new five-year, multi-million Dollar agreement focused on innovations in short-stature corn. This new program leverages Pairwise’s Fulcrum™ platform and builds on the success of the companies’ initial five-year collaboration for corn, soy, wheat, cotton, and canola. The upcoming collaboration between Pairwise and Bayer will be focused on optimizing and enhancing gene-edited short-stature corn for future use in Ba ..read more
Visit website
Heike Prinz appointed to Board of Management of Bayer AG
Bayer | Science For Better Life | Corporate News
by
7M ago
Leverkusen, August 21, 2023 – The Supervisory Board of Bayer AG has unanimously appointed Heike Prinz to Bayer’s Board of Management effective September 1, 2023. She will become the company’s Chief Talent Officer and Labor Director. This follows the mutual agreement by Board member Sarena Lin and Bayer’s Supervisory Board to not extend her contract beyond January 31, 2024.  Heike Prinz (58), most recently Head of Commercial Operations Europe, Middle East & Africa for Bayer’s Pharmaceutical Division, and a member of the Pharmaceuticals Executive Committee, has a nearly thirty-seve ..read more
Visit website
Aflibercept 8 mg first to achieve sustained vision gains with more than 70% of patients extended to intervals between 16 and 24 weeks in wet age-related macular degeneration at two years
Bayer | Science For Better Life | Corporate News
by
7M ago
Berlin, August 10, 2023 – Bayer today announced two-year (96 weeks) topline results of the pivotal clinical trial PULSAR in patients with neovascular (wet) age-related macular degeneration (nAMD). The data reinforce sustained vision gains with unprecedented extended treatment intervals of aflibercept 8 mg reaching up to 24 weeks with efficacy and safety comparable to the current standard of care Eylea™ (aflibercept 2 mg) with fixed intervals of 8 weeks. At two years (96 weeks), the aflibercept 8 mg combined groups demonstrated that 71% of patients reached a ≥16-week dosing interval, including ..read more
Visit website
Second quarter impacted by declines in glyphosate business
Bayer | Science For Better Life | Corporate News
by
7M ago
Leverkusen, August 8, 2023 – Bayer published detailed results for the second quarter of 2023 on Tuesday, after having already communicated key figures for the three-month period and lowering its outlook for full-year 2023 in a July 24 news release. The revised guidance was mainly due to a significant further decline in sales of glyphosate-based products at the Crop Science Division. Sales at Pharmaceuticals were stable on a currency- and portfolio-adjusted basis (Fx & portfolio adj.), while earnings were down year on year. Consumer Health registered higher sales (Fx & portfolio adj.) a ..read more
Visit website

Follow Bayer | Science For Better Life | Corporate News on FeedSpot

Continue with Google
Continue with Apple
OR